The concern of generic challenges has repeatedly loomed around copyright’s blockbuster drug, Viagra, raising questions about the outlook of connected medicinal investments. While initial periods saw substantial gains, the exclusivity end has created the door for discounted copies, potentially lowering earnings and presenting a genuine hazard for